Pasithea Therapeutics Corp.

Stage 4 · Declining · week 11→4 today

As of Oct 22, 2026, Pasithea Therapeutics is in Stage 4, the downtrend phase, now in its first week (since Oct 22, 2026). It closed at $0.45, 69.7% below its 52-week high and below its 200-day average, which is falling.

$0.45

-11.14% today

$14.9M · Micro cap

Market Neutral — Fading

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is KTTA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S4 70w

S4 25w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 3w → S2 4w → S3 3w → S4 14w → S1 7w → S4 3w → S1 5w → S4 70w → S1 8w → S4 3w → S1 4w → S2 7w → S3 5w → S4 25w → S1 5w → S4 1w current

Total tracked: 165 weeks across 16 stage runs.

KTTA among Biotechnology329th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…329	KTTAPasithea Therapeutics Corp.	Stage 4 · wk 1	27	−13.3%

vs 52W High

-69.7%

$0.29 lo$1.47 hi

69.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 1

1w13w26w

Week 1, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-31.3%

200 DMA: $0.65 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

2.17x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-13.3%

-2.2%

-35.4%

YTD

-62.6%

-41.6%

Scan Membership

Breakout Watch

Latest: 2023-09-06

2 appearances in last 60 days. First seen: 2022-09-30.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S41→4

Wk 1 · Vol 2.17x

2026-10-21S1

Wk 5 · Vol 4.82x

2026-10-20S1

Wk 5 · Vol 0.23x

2026-10-19S1

Wk 5 · Vol 0.10x

2026-10-16S1

Wk 5 · Vol 1.19x

2026-10-15S1

Wk 4 · Vol 0.11x

2026-10-14S1

Wk 4 · Vol 3.63x

2026-10-13S1

Wk 4 · Vol 0.34x

2026-10-12S1

Wk 4 · Vol 0.45x

2026-10-09S1

Wk 4 · Vol 0.32x

2026-10-08S1

Wk 3 · Vol 0.29x

2026-10-07S1

Wk 3 · Vol 0.67x

Moving averages & range

50 DMA

$0.50

200 DMA

$0.65

52W High

$1.47

52W Low

$0.29

5D Low

$0.41

Resistance levels (recent highs)

20d High

$0.50

60d High

$0.60

120d High

$0.85

250d High

$1.47

Next resistance

+12.5%

to 20d High

ROE

-65.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.3

Pasithea Therapeutics: quick answers

What stage is Pasithea Therapeutics in?

As of Oct 22, 2026, Pasithea Therapeutics (KTTA) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 22, 2026 and is in its first week there. What the four stages mean

Is Pasithea Therapeutics in an uptrend?

No. Pasithea Therapeutics is in a Stage 4 downtrend. It trades 31.3% below its 200-day average, which is falling.

How far is Pasithea Therapeutics from its 52-week high?

Pasithea Therapeutics closed at $0.45 on Oct 22, 2026, 69.7% below its 52-week high of $1.47. Its 52-week low is $0.29.

How has Pasithea Therapeutics performed over the past year?

As of Oct 22, 2026, Pasithea Therapeutics is down 41.6% over the past year and down 62.6% so far in 2026.

Which sector and industry is Pasithea Therapeutics in?

Pasithea Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.